Lupin on Friday said that its U.S. subsidiary Lupin Pharmaceuticals Inc. has launched its Niacin Extended-Release Tablets USP, 500 mg, 750 mg, 1000 mg strengths in the U.S. market after having received final approval from the U.S. Food and Drug Administration (FDA). A statement from the company said the tablets were the AB-rated generic equivalent of AbbVie Inc.’s Niaspan Tablets 500 mg, 750 mg, 1000 mg and used with diet to reduce elevated TC, LDL-C, Apo B and TG levels, and to increase HDL-C in patients with primary hyperlipidemia and mixed dyslipidemia. — Special Correspondent